PACK-CXL vs. antimicrobial therapy for bacterial, fungal, and mixed infectious keratitis: a prospective randomized phase 3 trial.

"Declarations Ethics approval and consent to participateThe Institutional Review Boards of all study sites involved prospectively approved the study protocol, which adhered to all local laws and the tenets of the Declaration of Helsinki, and written informed consent was obtained by all participants before inclusion. Consent for publicationNot applicable. Competing interestsFarhad Hafezi is the chief scientific officer of EMAGine AG (Zug, Switzerland), co-inventor of the PCT applications CH2012/0000090 and PCT2014/CH000075 regarding CXL technology, and an editorial board member of the journal. The other authors have no competing interest in the materials presented herein. Competing interests Farhad Hafezi is the chief scientific officer of EMAGine AG (Zug, Switzerland), co-inventor of the PCT applications CH2012/0000090 and PCT2014/CH000075 regarding CXL technology, and an editorial board member of the journal. The other authors have no competing interest in the materials presented herein."

"Funding This study was supported by the Light for Sight Foundation, Zurich, Switzerland. SOOFT Italia S.p.A. (Montegiorgio, Italy) provided the riboflavin solution used in this study free of charge."

"Trial registration This trial is registered at ClinicalTrials.gov, trial registration number: NCT02717871"